학술논문
Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the 'Rete Ematologica Pugliese E Basilicata'.
Document Type
Letter
Author
Mele, Giuseppe; Pastore, Domenico; Di Renzo, Nicola; Fragasso, Alberto; Guarini, Attilio; Mazza, Patrizio; Musto, Pellegrino; Pavone, Vincenzo; Tarantini, Giuseppe; Curci, Paola; Falcone, Antonietta Pia; Mele, Anna; Miccolis, Maria Rosanna; Palazzo, Giulia; Palumbo, Gaetano; Quinto, Angela Maria; Reddiconto, Giovanni; Rizzi, Rita; Cascavilla, Nicola; Specchia, Giorgina
Source
Subject
*RESPIRATORY infections
Language
ISSN
1042-8194
Abstract
The European regulatory authority has approved the combination of I POM + LoDEX i for patients with relapsed and refractory multiple myeloma (RRMM) who have undergone at least two prior therapies including lenalidomide and bortezomib. The starting dose was 4 mg pomalidomide in 85 patients (82.5%), and 3 mg pomalidomide in 6 patients (6%) or 2 mg pomalidomide in 12 patients (11.5%) due to an absolute neutrophil count lower than 1.0 × 10 SP 3 sp /µL, or a platelets count below 20 × 10 SP 3 sp /µL or ECOG PS > 2. Dose reduction was necessary for 27% of patients due to hematological toxicity grade 3/4 (50% of patients) and non-hematological toxicity (50% of patients). Neutropenia was the most common hematologic adverse event and occurred in 32% of patients; thrombocytopenia occurred in 8.5% of patients, anemia in 9.5% of patients. [Extracted from the article]